Clinical Trial Update: Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether adding the P-glycoprotein modulator valspodar to standard chemotherapy improves outcomes in adults with previously untreated ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Inv
• Acute Myeloid Leukemia with Maturation
• Acute Myeloid Leukemia with Minimal Differentiation
• Erythroleukemia
• Monocytic Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• Valspodar (valspodar)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 3 | Status: COMPLETED